Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

PharmaEssentia Publishes Results for Polycythemia Vera Therapy

publication date: Apr 2, 2024

Taiwan’s PharmaEssentia reported positive data from studies of its ropeginterferon alfa-2b (BESREMi®) therapy in patients with polycythemia vera (PV), a type of chronic leukemia (blood cancer) that causes bone marrow to overproduce red blood cells. The company said a 250–350–500 µg dosing regimen had the highest probability of a complete hematologic response with acceptable safety. The data was from an exposure–response analyses of the drug. PharmaEssentia published the results in the British Journal of Clinical Pharmacology. More details...



Share this with colleagues:

 


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital